{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T22:40:01Z","timestamp":1754174401869,"version":"3.41.2"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Early during the Coronavirus disease 2019 (Covid-19) pandemic, concerns were raised regarding potential adverse outcomes in patients taking angiotensin-converting enzyme inhibitors (ACEIs)\/angiotensin receptor blockers (ARBs). These concerns were based on animal studies showing increased ACE-2 expression in mice treated with ACEI\/ARB. This is a single-center, retrospective, cohort study of 289 patients diagnosed with 2019 Novel Coronavirus (SARS-CoV-2) hospitalized between March of 2020 and June of 2020. The study was intended to investigate the impact of ACEIs and\/or ARBs on in-hospital mortality, intensive care unit (ICU) admission, postadmission hemodialysis requirement, and the need for mechanical ventilation in patients with COVID-19. This cohort of 289 patients included 139 of 289 women (48%) with a mean age of 61 \u00b1 19 years. Patients using ACEIs\/ARBs were older (69.68 vs. 57.9 years; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0001), more likely to have a history of hypertension (97% vs. 36%; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0001), diabetes mellitus (48% vs. 20.9%; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0001), chronic heart failure (11.39% vs. 4.29%; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0512), coronary artery disease (20.25% vs. 7.14%; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0025), stroke\/Transient Ischemic Attack (7.59% vs. 2.38%; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0761), chronic kidney disease (11.39% vs. 3.33%; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0167), atrial fibrillation\/flutter (18.99% vs. 7.14%; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0080), and dementia (22.7% vs. 11.4%; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0233) compared with the nonuser group. There was significantly higher in-hospital mortality in patients using ACEIs\/ARBs than nonusers, respectively (32.9% vs. 15.2%; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0015). However, a multivariate logistics regression analysis performed to adjust for common confounders demonstrated no significant difference in all-cause in-patient mortality (<jats:italic toggle=\"yes\">P<\/jats:italic> 0.7141). Admission to ICU, postadmission hemodialysis requirement, and mechanical ventilation showed no significant differences between the 2 groups (<jats:italic toggle=\"yes\">P<\/jats:italic> = NS). This study suggests that the use of ACEIs and ARBs in patients with COVID-19 was not found to significantly increase all-cause in-hospital mortality, ICU admissions, and hemodialysis and mechanical ventilation requirements.<\/jats:p>","DOI":"10.1097\/fjc.0000000000001189","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T20:08:45Z","timestamp":1638562125000},"page":"311-314","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Renin\u2013Angiotensin System Blocker in COVID-19. A Single Center Study."],"prefix":"10.1097","volume":"79","author":[{"given":"Riya","family":"Job","sequence":"first","affiliation":[{"name":"Medicine; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Abdul Qader","sequence":"additional","affiliation":[{"name":"Medicine; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Torres","sequence":"additional","affiliation":[{"name":"Medicine; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baher","family":"Al Abbasi","sequence":"additional","affiliation":[{"name":"Medicine; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nakeya","family":"Dewaswala","sequence":"additional","affiliation":[{"name":"Medicine; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Abdallah","sequence":"additional","affiliation":[{"name":"Medicine; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Chen","sequence":"additional","affiliation":[{"name":"Medicine; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesus E.","family":"Pino","sequence":"additional","affiliation":[{"name":"Cardiology, University of Miami\/JFK Medical Center Palm Beach Regional GME Consortium, Atlantis, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert D.","family":"Chait","sequence":"additional","affiliation":[{"name":"Cardiology, University of Miami\/JFK Medical Center Palm Beach Regional GME Consortium, Atlantis, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,3]]},"reference":[{"key":"R2-20250802","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1161\/01.HYP.0000196268.08909.fb","article-title":"Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation","volume":"47","author":"Ferrario","year":"2006","journal-title":"Hypertension"},{"key":"R4-20250802","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72\u202f314 cases from the Chinese center for disease control and prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"R5-20250802","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40618-020-01318-1","article-title":"COVID-19: is there a link between the course of infection and pharmacological agents in diabetes?","volume":"43","author":"Filardi","year":"2020","journal-title":"J Endocrinol Invest."},{"key":"R6-20250802","first-page":"m1313","article-title":"Drugs and the renin-angiotensin system in COVID-19","volume":"369","author":"A","year":"2020","journal-title":"BMJ."},{"key":"R7-20250802","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13054-020-02862-1","article-title":"COVID-19 and the RAAS-a potential role for angiotensin II?","volume":"24","author":"B","year":"2020","journal-title":"Crit Care."},{"key":"R8-20250802","doi-asserted-by":"crossref","first-page":"H1080","DOI":"10.1152\/ajpheart.00215.2020","article-title":"Letter to the Editor: angiotensin-converting enzyme 2: an ally or a Trojan horse? Implications to SARS-CoV-2-related cardiovascular complications","volume":"318","author":"A","year":"2020","journal-title":"Am J Physiol Heart circulatory Physiol."},{"key":"R9-20250802","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/HJH.0000000000002450","article-title":"Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?","volume":"38","author":"E","year":"2020","journal-title":"J Hypertens."},{"key":"R10-20250802","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/eurheartj\/ehaa235","article-title":"SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?","volume":"41","author":"K","year":"2020","journal-title":"Eur Heart J."},{"key":"R11-20250802","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/thoraxjnl-2020-215322","article-title":"Renin-angiotensin system blocker and outcomes of COVID-19: a systematic review and meta-analysis","volume":"76","author":"Lee","year":"2021","journal-title":"Thorax"},{"key":"R12-20250802","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19","volume":"382","author":"Vaduganathan","year":"2020","journal-title":"N Engl J Med."},{"key":"R13-20250802","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1042\/CS20200163","article-title":"Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?","volume":"134","year":"2020","journal-title":"Clin Sci (Lond)."}],"container-title":["Journal of Cardiovascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FJC.0000000000001189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T22:01:33Z","timestamp":1754172093000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FJC.0000000000001189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":11,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/fjc.0000000000001189","relation":{},"ISSN":["0160-2446"],"issn-type":[{"type":"print","value":"0160-2446"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"2021-06-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}